Dowsett M - Search Results

1

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.

Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Martin LA, et al. Among authors: dowsett m. J Biol Chem. 2003 Aug 15;278(33):30458-68. doi: 10.1074/jbc.M305226200. Epub 2003 May 29. J Biol Chem. 2003. PMID: 12775708 Free article.

2

Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.

Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M. Chan CM, et al. Among authors: dowsett m. J Steroid Biochem Mol Biol. 2002 Aug;81(4-5):333-41. doi: 10.1016/s0960-0760(02)00074-2. J Steroid Biochem Mol Biol. 2002. PMID: 12361723

3

Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.

Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. Come SE, et al. Among authors: dowsett m. Clin Cancer Res. 2003 Jan;9(1 Pt 2):443S-6S. Clin Cancer Res. 2003. PMID: 12538498 Review. No abstract available.

4

Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M. Johnston SR, et al. Among authors: dowsett m. Clin Cancer Res. 2003 Jan;9(1 Pt 2):524S-32S. Clin Cancer Res. 2003. PMID: 12538510 Review.

5

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.

Johnston SR, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer P, Howes A. Johnston SR, et al. Among authors: dowsett m. J Clin Oncol. 2003 Jul 1;21(13):2492-9. doi: 10.1200/JCO.2003.10.064. J Clin Oncol. 2003. PMID: 12829668 Clinical Trial.

6

Mechanisms of resistance to aromatase inhibitors.

Dowsett M, Martin LA, Smith I, Johnston S. Dowsett M, et al. J Steroid Biochem Mol Biol. 2005 May;95(1-5):167-72. doi: 10.1016/j.jsbmb.2005.04.022. J Steroid Biochem Mol Biol. 2005. PMID: 15982868 Review.

7

Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.

Johnston SR, Martin LA, Head J, Smith I, Dowsett M. Johnston SR, et al. Among authors: dowsett m. J Steroid Biochem Mol Biol. 2005 May;95(1-5):173-81. doi: 10.1016/j.jsbmb.2005.04.004. J Steroid Biochem Mol Biol. 2005. PMID: 15996863 Review.

8

Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.

Chen B, Gajdos C, Dardes R, Kidwai N, Johnston SR, Dowsett M, Jordan VC. Chen B, et al. Among authors: dowsett m. Int J Oncol. 2005 Aug;27(2):327-35. Int J Oncol. 2005. PMID: 16010412

9

Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.

Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M. Martin LA, et al. Among authors: dowsett m. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S75-84. doi: 10.1677/erc.1.01023. Endocr Relat Cancer. 2005. PMID: 16113101

10

Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.

Dowsett M, Nicholson RI, Pietras RJ. Dowsett M, et al. Breast Cancer Res Treat. 2005;93 Suppl 1:S11-8. doi: 10.1007/s10549-005-9037-3. Breast Cancer Res Treat. 2005. PMID: 16247595 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

739 results

Search Page

Filters